Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
|
US |
|
Park Hotels & Resorts Inc
NYSE:PK
|
US |
|
M
|
Marriott International Inc
SWB:MAQ
|
US |
|
Bukit Asam Tbk PT
OTC:PBATF
|
ID |
|
Tri Banyan Tirta Tbk PT
IDX:ALTO
|
ID |
|
S
|
Severstal' PAO
LSE:SVST
|
RU |
|
T
|
Trinity Capital Inc
F:9F7
|
US |
|
Freehold Royalties Ltd
TSX:FRU
|
CA |
|
Elixirr International PLC
LSE:ELIX
|
UK |
|
AmorePacific Corp
KRX:090430
|
KR |
|
N
|
Noram Drilling AS
OSE:NORAM
|
NO |
|
B
|
BNP Paribas SA
DUS:BNP
|
FR |
|
P
|
Prudential PLC
XHAM:PRU
|
UK |
|
Jyske Bank A/S
CSE:JYSK
|
DK |
|
C
|
CLARIVATE PLC
F:16A
|
UK |
|
Acousort AB
F:4SA
|
SE |
|
LENSAR Inc
NASDAQ:LNSR
|
US |
|
C
|
Cuscal Ltd
ASX:CCL
|
AU |
|
F
|
Farmacosmo SpA
MIL:COSMO
|
IT |
Wall St Price Targets
RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for RARE is 53.1 USD with a low forecast of 27.27 USD and a high forecast of 100.8 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RARE's stock price target?
Price Target
53.1
USD
According to Wall Street analysts, the average 1-year price target for RARE is 53.1 USD with a low forecast of 27.27 USD and a high forecast of 100.8 USD.
What is the Revenue forecast for Ultragenyx Pharmaceutical Inc?
Projected CAGR
23%
The compound annual growth rate for Revenue over the next 8 years is 23%.
What is the Gross Profit forecast for Ultragenyx Pharmaceutical Inc?
Projected CAGR
23%
The compound annual growth rate for Gross Profit over the next 7 years is 23%.
